Navigation Links
Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Date:4/24/2012

NATICK, Mass., April 24, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces CE Mark and European market launch of the Emerge™ PTCA[1] Dilatation Catheter.  The Emerge Catheter is a next-generation pre-dilatation balloon catheter designed specifically to offer exceptional deliverability to address challenging lesions.  The company plans to launch the product immediately in CE Mark countries in both Monorail® and Over-The-Wire (OTW) options.  Commercial availability is expected in the U.S. and additional international markets later this year.

The Emerge PTCA Dilatation Catheter includes a 1.2 mm diameter balloon option that features an ultra-low 0.017" tip profile and low crossing profiles designed to cross tight lesions.  The Emerge 1.2 mm balloon also employs a durable balloon material that provides high rated burst pressure (18 ATM) for sizing flexibility.  The Emerge Catheter platform offers a reduced, low-friction shaft profile which allows for simultaneous use of two Monorail balloon catheters in a 6F guide catheter and two OTW balloon catheters in an 8F guide catheter.

"The Emerge Catheter combines several innovative balloon technologies in a single versatile platform," said Jean Fajadet, M.D., Clinique Pasteur, Toulouse, France, who performed the first procedure in Europe with the Emerge PTCA Dilatation Catheter.  "The result is a functional catheter with a low profile and excellent deliverability to facilitate the navigation and crossing of challenging coronary lesions."

The Emerge Catheter is available in a wide array of balloon diameters from 1.2 mm up to 4.0 mm, with balloon lengths ranging from 8 mm up to 30 mm.  Both the Monorail and OTW catheters are available with two distinct shaft technologies designed to provide versatility in addressing different clinical situations.  The "Push Technology" (1.2 mm and 1.5 mm) offers a single-segment inner shaft for enhanced pushability.  The "Workhorse Technology" (1.2 mm to 4.0 mm) features a Bi-Segment inner shaft designed for excellent deliverability without sacrificing push.  

"The Emerge Catheter builds on Boston Scientific's expertise in developing leading catheter technology and our commitment to offering the most advanced devices to treat coronary artery disease," said Kevin Ballinger, president of Boston Scientific's cardiovascular division. "The innovative features and broad range of available options for the Emerge platform enables physicians to select the appropriate catheter based on clinical need, helping to improve outcomes for patients undergoing coronary interventions."

Coronary artery disease represents the leading cause of death in the United States and Europe, accounting for more than 870,000 U.S. deaths each year and 1.95 million deaths annually in Europe[2].  PTCA dilatation catheters are used in coronary angioplasty and stenting procedures to open arteries blocked by atherosclerosis, which if left untreated can cause heart attack and stroke.  

The Emerge 1.2 mm and 1.5 mm PTCA Dilatation Catheters are currently under review by the U.S. Food and Drug Administration, and are not available for sale in the United States.

About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding our business plans, new product launches and launch cadence, regulatory approvals, product performance and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. 

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.

[1] Percutaneous Transluminal Coronary Angioplasty

[2] Source: American Heart Association

 CONTACT: Steven Campanini 508-652-5740 (office) Media Relations Boston Scientific Corporation steven.campanini@bsci.com Sean Findlen 617-520-7268  (office) Media Relations Weber Shandwick sfindlen@webershandwick.comSean Wirtjes508-652-5305 (office)Investor RelationsBoston Scientific Corporationinvestor_relations@bsci.com 


'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... HONG KONG , May 24, 2016 ... de COMBO ™ , la ... présentent des cathéters destinés à l,intervention portant ... artério-veineuse (FAV)   OrbusNeich, entreprise ... vasculaires permettant de changer la vie, a ...
(Date:5/24/2016)... Dutch surgeons have launched a ground-breaking medical app to help doctors ... a global scale. Medical professionals from Europe , ... the US have already signed up for the app, which combines ... environment. Education  "Imagine a doctor for Medicines ... at Harvard to treat a bomb victim via live streaming - ...
(Date:5/23/2016)... India , May 23, 2016 ... report "Patient Handling Equipment Market by Product (Wheelchair, ... of Care (Bariatric Care, Critical Care, Wound), Accessories ... - Forecast to 2021", published by MarketsandMarkets, the ... USD 17.18 Billion by 2021 at a CAGR ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... PhysicianOne Urgent Care, advocators in ... tick bites and how to avoid being bitten this spring. , The official ... , Ticks, small spider-like insects, are known for attaching themselves to their prey while ...
(Date:5/24/2016)... , ... May 24, 2016 ... ... of Essette Dashboard, its highly anticipated, web-based software module. The cutting-edge feature ... application’s “secret sauce”? Integration with Izenda’s self-service business intelligence solution and its ...
(Date:5/24/2016)... Brighton, TN (PRWEB) , ... May 24, 2016 ... ... prenatal vitamin alkaline water, a revolutionary new beverage for pregnant women to prevent ... essential prenatal vitamins and alkaline minerals with the look and taste of water. ...
(Date:5/23/2016)... ... May 23, 2016 , ... Edward D. Buckingham, M.D . is excited ... The annual roster is put out by the National Consumer Advisory Board to honor ... care are considered for this award. , The National Consumer Advisory Board (NCAB) is ...
(Date:5/23/2016)... ... 23, 2016 , ... According to an article published May 11th ... birth of her son, Rockwell Lloyd Liu, and notes that gestational surrogacy helped make ... Bill” star explains that, as a career oriented single woman, gestational surrogacy made parenthood ...
Breaking Medicine News(10 mins):